Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 2/20 | 0.48 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 4/20 | 0.41 |
| ▸ | PPARD | Q03181 | 4/20 | 0.41 |
| ▸ | PPARA | Q07869 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL27083092 | 0.98 | SMPD1 (0.50) | FDPSSMPD1CES2PPARGPPARD | |
| Acetic Acid SCHEMBL3140123 | 0.93 | FDPS (0.47) | FDPSSMPD1AKR1B1CES2PPARG | |
| Acetic Acid SCHEMBL11691620 | 0.91 | SMPD1 (0.48) | FDPSSMPD1CES2PPARGPPARD | |
| Acetic Acid SCHEMBL3139399 | 0.91 | SMPD1 (0.48) | FDPSSMPD1CES2PPARGPPARD | |
| Acetic Acid SCHEMBL4367052 | 0.91 | SMPD1 (0.48) | FDPSSMPD1CES2PPARGPPARD | |
| Acetic Acid SCHEMBL9224621 | 0.91 | SMPD1 (0.48) | FDPSSMPD1CES2PPARGPPARD | |
| Pivalate SCHEMBL3414635 | 0.89 | SMPD1 (0.47) | FDPSSMPD1CES2PPARGPPARD | |
| Glycolic Acid SCHEMBL23466939 | 0.87 | SMPD1 (0.46) | FDPSSMPD1PPARGPPARDPPARA | |
| Propionic Acid SCHEMBL4938562 | 0.87 | SMPD1 (0.46) | FDPSSMPD1PPARGPPARDPPARA | |
| Valeric Acid SCHEMBL3410666 | 0.87 | AKR1B1 (0.58) | AKR1B1PPARGPPARDPPARATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866754-B2 | Trinucleotide mRNA cap analogs | MODERNATX, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| EP-4086269-A1 | MRNA CAP ANALOGS WITH MODIFIED PHOSPHATE LINKAGE | ModernaTX, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| EP-3362461-B1 | MRNA CAP ANALOGS WITH MODIFIED PHOSPHATE LINKAGE | MODERNATX INC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20190225644-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | MODERNATX, INC. | 2019-07-25 | — | — | US | disclosed |
| US-20190211368-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | MODERNATX, INC. | 2019-07-11 | — | — | US | disclosed |
| EP-3362460-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | Modernatx, Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017066789-A1 | MRNA CAP ANALOGS WITH MODIFIED SUGAR | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066797-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066793-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066791-A1 | SUGAR SUBSTITUTED MRNA CAP ANALOGS | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| EP-2596005-A2 | ANTIVIRAL AGENTS | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2013-05-29 | — | — | EP | disclosed |
| US-20120010164-A1 | ANTIVIRAL AGENTS | SURNMA VINCENZO (IT) | 2012-01-12 | — | — | US | disclosed |
| US-20110306573-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF VIRAL POLYMERASES | MERCK SHARP & DOHME CORP. | 2011-12-15 | — | — | US | disclosed |
| EP-2324043-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF VIRAL POLYMERASES | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010084115-A2 | ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010026153-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF VIRAL POLYMERASES | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190211368-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | RNGTT, RNMT, CPSF7 | FDPS 2005/4885SMPD1 2032/4885AKR1B1 4271/4885 |
| US-20120010164-A1 | ANTIVIRAL AGENTS | EIF2AK2, HAVCR2, MAVS | FDPS 949/4885SMPD1 1005/4885AKR1B1 2677/4885 |
| US-11866754-B2 | Trinucleotide mRNA cap analogs | RNGTT, RNMT, CPSF7 | FDPS 2005/4885SMPD1 2032/4885AKR1B1 4271/4885 |
| US-20190225644-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | RNGTT, RNMT, NSUN2 | FDPS 1851/4885SMPD1 1445/4885AKR1B1 4248/4885 |
| US-20110306573-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF VIRAL POLYMERASES | POLR2E, POLR2H, POLRMT | FDPS 1264/4885SMPD1 1986/4885AKR1B1 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.